I don't really understand so go straight to your doctor about its usefulness for your next stroke.
http://www.ncbi.nlm.nih.gov/pubmed/22587708
Cui J1,
Chen S,
Zhang C,
Meng F,
Wu W,
Hu R,
Hadass O,
Lehmidi T,
Blair GJ,
Lee M,
Chang M,
Mobashery S,
Sun GY,
Gu Z.
Abstract
BACKGROUND:
Cerebral
ischemia has been shown to induce activation of matrix
metalloproteinases (MMPs), particularly MMP-9, which is associated with
impairment of the neurovasculature, resulting in blood-brain barrier
breakdown, hemorrhage and neurodegeneration. We previously reported that
the thiirane inhibitor SB-3CT, which is selective for gelatinases
(MMP-2 and -9), could antagonize neuronal apoptosis after transient
focal cerebral ischemia.
RESULTS:
Here, we used a
fibrin-rich clot to occlude the middle cerebral artery (MCA) and
assessed the effects of SB-3CT on the neurovasculature. Results show
that neurobehavioral deficits and infarct volumes induced by embolic
ischemia are comparable to those induced by the filament-occluded
transient MCA model. Confocal microscopy indicated embolus-blocked brain
microvasculature and neuronal cell death. Post-ischemic SB-3CT
treatment attenuated infarct volume, ameliorated neurobehavioral
outcomes, and antagonized the increases in levels of proform and
activated MMP-9. Embolic ischemia caused degradation of the
neurovascular matrix component laminin and tight-junction protein ZO-1,
contraction of pericytes, and loss of lectin-positive brain
microvessels. Despite the presence of the embolus, SB-3CT mitigated
these outcomes and reduced hemorrhagic volumes. Interestingly, SB-3CT
treatment for seven days protected against neuronal laminin degradation
and protected neurons from ischemic cell death.
CONCLUSION:
These
results demonstrate considerable promise for the thiirane class of
selective gelatinase inhibitors as potential therapeutic agents in
stroke therapy.
No comments:
Post a Comment